“An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III Post author:Sam Post published:February 13, 2018 Post category:BioPharma Alzheimer’s drug development took another hit. Source: BioSpace You Might Also Like Novartis AG Lures Superstar Scientist Away From UCSF August 16, 2017 Filings Reveal Concert Pharma Spurned $250 Million Buyout Offer From Vertex in November 2016 March 26, 2017 Johns Hopkins Gets a $65M Boost to Take Promising Drugs Into Clinic November 15, 2017
Filings Reveal Concert Pharma Spurned $250 Million Buyout Offer From Vertex in November 2016 March 26, 2017
